{"title":"重组人脑利钠肽联合左西孟旦对心力衰竭患者血清白细胞介素-6、肿瘤坏死因子-a、d -二聚体的影响。","authors":"Yujing Zhang, Pingyan Fei, Xinyu Liu","doi":"10.5937/jomb0-56202","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the impact of recombinant human brain natriuretic peptide (Rh-BNP) combined with levosimendan on therapeutic efficacy, inflammatory markers, and nutritional status in patients with heart failure (HF).</p><p><strong>Methods: </strong>A total of 162 heart failure patients treated between March 2022 and March 2024 were randomly assigned to three treatment groups: Group 1 received conventional therapy plus Rh-BNP Group 2 received conventional therapy plus levosimendan, and Group 3 received a combination of both Rh-BNP and levosimendan, along with nutritional support. Efficacy was assessed regarding cardiac function, renal function, inflammatory biomarkers (IL-6, TNF-a), nutritional status, and quality of life.</p><p><strong>Results: </strong>All three treatment groups improved cardiac and renal function, reduced inflammatory markers, and enhanced nutritional status. However, the combination therapy group (Group 3) demonstrated the most significant improvements across all parameters, including a greater reduction in IL-6 and TNF-a levels and an improvement in the Mini Nutritional Assessment (MNA) score. Additionally, the combination treatment led to marked improvements in quality of life and reduced symptoms of depression and anxiety compared to the other groups (P< 0.05).</p><p><strong>Conclusions: </strong>Rh-BNP combined with levosimendan, alongside nutritional support, offers significant benefits in treating heart failure, enhancing cardiac function, reducing inflammation, improving nutritional status, and improving the overall quality of life for patients.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"1100-1109"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433298/pdf/","citationCount":"0","resultStr":"{\"title\":\"Serum interleukin-6, tumour necrosis factor-a, D-dimer after recombinant human brain natriuretic peptide combined with levosimendan in patients with heart failure.\",\"authors\":\"Yujing Zhang, Pingyan Fei, Xinyu Liu\",\"doi\":\"10.5937/jomb0-56202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study evaluates the impact of recombinant human brain natriuretic peptide (Rh-BNP) combined with levosimendan on therapeutic efficacy, inflammatory markers, and nutritional status in patients with heart failure (HF).</p><p><strong>Methods: </strong>A total of 162 heart failure patients treated between March 2022 and March 2024 were randomly assigned to three treatment groups: Group 1 received conventional therapy plus Rh-BNP Group 2 received conventional therapy plus levosimendan, and Group 3 received a combination of both Rh-BNP and levosimendan, along with nutritional support. Efficacy was assessed regarding cardiac function, renal function, inflammatory biomarkers (IL-6, TNF-a), nutritional status, and quality of life.</p><p><strong>Results: </strong>All three treatment groups improved cardiac and renal function, reduced inflammatory markers, and enhanced nutritional status. However, the combination therapy group (Group 3) demonstrated the most significant improvements across all parameters, including a greater reduction in IL-6 and TNF-a levels and an improvement in the Mini Nutritional Assessment (MNA) score. Additionally, the combination treatment led to marked improvements in quality of life and reduced symptoms of depression and anxiety compared to the other groups (P< 0.05).</p><p><strong>Conclusions: </strong>Rh-BNP combined with levosimendan, alongside nutritional support, offers significant benefits in treating heart failure, enhancing cardiac function, reducing inflammation, improving nutritional status, and improving the overall quality of life for patients.</p>\",\"PeriodicalId\":16175,\"journal\":{\"name\":\"Journal of Medical Biochemistry\",\"volume\":\"44 5\",\"pages\":\"1100-1109\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433298/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Biochemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5937/jomb0-56202\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-56202","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Serum interleukin-6, tumour necrosis factor-a, D-dimer after recombinant human brain natriuretic peptide combined with levosimendan in patients with heart failure.
Background: This study evaluates the impact of recombinant human brain natriuretic peptide (Rh-BNP) combined with levosimendan on therapeutic efficacy, inflammatory markers, and nutritional status in patients with heart failure (HF).
Methods: A total of 162 heart failure patients treated between March 2022 and March 2024 were randomly assigned to three treatment groups: Group 1 received conventional therapy plus Rh-BNP Group 2 received conventional therapy plus levosimendan, and Group 3 received a combination of both Rh-BNP and levosimendan, along with nutritional support. Efficacy was assessed regarding cardiac function, renal function, inflammatory biomarkers (IL-6, TNF-a), nutritional status, and quality of life.
Results: All three treatment groups improved cardiac and renal function, reduced inflammatory markers, and enhanced nutritional status. However, the combination therapy group (Group 3) demonstrated the most significant improvements across all parameters, including a greater reduction in IL-6 and TNF-a levels and an improvement in the Mini Nutritional Assessment (MNA) score. Additionally, the combination treatment led to marked improvements in quality of life and reduced symptoms of depression and anxiety compared to the other groups (P< 0.05).
Conclusions: Rh-BNP combined with levosimendan, alongside nutritional support, offers significant benefits in treating heart failure, enhancing cardiac function, reducing inflammation, improving nutritional status, and improving the overall quality of life for patients.
期刊介绍：
The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly.
The Journal publishes original scientific and specialized articles on all aspects of
clinical and medical biochemistry,
molecular medicine,
clinical hematology and coagulation,
clinical immunology and autoimmunity,
clinical microbiology,
virology,
clinical genomics and molecular biology,
genetic epidemiology,
drug measurement,
evaluation of diagnostic markers,
new reagents and laboratory equipment,
reference materials and methods,
reference values,
laboratory organization,
automation,
quality control,
clinical metrology,
all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
